GRA VentureLab company helping to develop promising cancer vaccine
GRA VentureLab company Viamune will help to develop and commercialize a promising new cancer vaccine and the technologies used to create it. Based on the work of researchers at the University of Georgia and the Mayo Clinic, the vaccine dramatically reduces tumors in a mouse model that mimics 90 percent of human breast and pancreatic cancer cases, including those resistant to common treatments. According to the researchers, the vaccine elicits a very strong immune response, activating all three components of the immune system to reduce tumor size by an average of 80 percent.
If all goes well, the researchers hope to begin to test the safety of the vaccine in humans in late 2013. Read more>